Revolution Medicines jobs

Associate Director, Global Commercialization Systems Enablement Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Global Commercialization Systems Enablement is responsible for coordinating and enabling Commercial and Medical Affairs global systems work across markets outside the United States. This role ensures that regional needs are clearly understood, refined, and effectively integrated into established global processes, including launch orchestration, compliance frameworks, software development lifecycle practices, and prioritization governance. For new market launches outside of the United States, this individual will lead the associated Commercial and Medical business systems workstreams, ensuring coordinated planning, readiness, and execution across regional IT teams, global Commercial and Medical solution teams, and enterprise technology teams. The Associate Director adds value by clarifying requirements, identifying cross market commonalities, and reducing discovery work for global delivery teams such as Omnichannel Solutions, Data Solutions, Medical Affairs Solutions, and Field Solutions. The role supports seamless pull through of work into global intake and execution models, helping

Scientific Writer, Integrated Research Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Scientific Writer with strong nonclinical regulatory experience to support the authoring and integration of nonclinical content for U.S. and global regulatory submissions. This role focuses on developing and integrating nonclinical content beyond INDs and NDAs, including briefing documents, Investigator Brochures, responses to health authority questions, and other submission-related materials across the U.S., Europe, and Asia. As a strategic scientific integrator, this individual will translate complex RAS biology and translational pharmacology into clear, compelling regulatory narratives that reflect RevMed's deep mechanistic understanding of RAS signaling and frontier targets. The role partners closely with nonclinical subject matter experts (SMEs) in pharmacology, toxicology, and DMPK, as well as Regulatory Affairs, Regulatory Operations, and Medical Writers, to ensure nonclinical strategy and content are scientifically rigorous, aligned, and submission-ready. The Scientific Writer will leverage structured source documents, document management systems, and emerging AI-enabled

Executive Director, Global Commercial Lead Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, Global Commercial Development Disease Area Lead, this newly created role will serve as a leader for continuing to build our global oncology marketing capabilities driving global commercial strategy at product team and overseeing global launch strategy and lifecycle planning for a given indication/indications. Candidates should be passionate about leading cross-functional collaboration, and contributing as both a strategic leader and hands-on driver in a growing organization. This position is primarily remote with travel required for scientific and team meetings. Specifically, you will be responsible for: - Partner across the company including with clinical development, medical affairs, market access, to drive indication strategy, shape brand strategies across the product team. - Ensure global readiness to drive successful launch planning, commercialization, and performance tracking across the U.S. and key ex-U.S. markets. - Execute global disease area strategy, brand strategies, including branding,

Lab Automation Engineer Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an Associate Automation Engineer to join our laboratory automation team. The successful candidate will support the day-to-day operation, maintenance, troubleshooting, and optimization of automated laboratory instrumentation and integrated automation systems. This individual will work closely with scientists, engineers, and cross-functional teams to ensure reliable laboratory operations and support automation-driven workflows. The ideal candidate will have hands-on experience with laboratory automation platforms, instrumentation support, software-driven workflows, equipment validation, and troubleshooting of mechanical systems, along with a strong interest in process improvement and operational efficiency. As a member of the Automation Engineering team, you will contribute to the team with accountability for the following: - Develop and maintain automation methods using laboratory control platforms such as Tecan FluentControl, Hamilton Venus, Agilent VWorks, HighRes Cellario Scheduler, and Beckman Coulter Tempo/Echo. - Provide hands-on support, troubleshooting, and maintenance for automated laboratory instrumentation and integrated automation

Associate Director, Integrated Research Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Integrated Research Management provides leadership across Research disciplines to strengthen operational execution, organizational clarity, and cross-functional alignment within the Discovery organization. This role translates Research strategy into actionable discipline-level plans and drives operational effectiveness within and across scientific teams. The Associate Director partners with Research leadership to identify business and scientific challenges, improve operating frameworks, and implement scalable solutions that support Discovery performance and organizational growth. - Translate Research strategy into clear operating plans and drive disciplined execution across Discovery workflows. - Establish and enforce operational objectives, processes, and decision frameworks that improve cross-disciplinary coordination and execution performance. - Diagnose and resolve complex operational challenges, removing friction and strengthening clarity, speed, and accountability in program advancement. - Lead and implement change initiatives within Research, ensuring stakeholder alignment and sustained adoption of improved processes and digital tools. - Partner directly

Director, Global Regulatory Affairs Project Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Global Regulatory Affairs Project Management is an integral part of the global Regulatory Affairs organization and is responsible for translating global regulatory strategies into actionable execution plans. This role applies advanced project management expertise and operational leadership to guide cross-functional teams, supporting planned and ongoing drug marketing applications across RevMed programs. The role partners closely with Global Regulatory Science and Global Filing and Registration and contributes to the broader Global Regulatory Affairs function at RevMed. This position reports to the Senior Director, Global Regulatory Affairs Project Management. The ideal candidate will have an in-depth understanding of oncology drug development and demonstrated hands-on regulatory project management experience supporting early- and late-stage registrational programs, including the execution of global new drug marketing applications, in alignment with corporate objectives. Core Responsibilities: - Project manage regulatory submissions from initiation through submission, supporting the

Executive Director, Computational Systems Biology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As an Executive Director and Head of Research Computational Biology within our Biology Function, the individual will oversee the scientific and strategic direction of systems biology research and preclinical computational biology initiatives. The individual will lead a team of computational biologists and bioinformaticians focused on acquisition, organization, and analysis of large multi-omics data sets, using both public and proprietary data sources, that will help inform treatment strategies and guide patient stratification for a growing pipeline of RAS(ON) and targeted oncology therapeutics. We are looking for an experienced leader with strong interpersonal skills and an ability to lead a strong and diverse computational biology team. Key aspects of the role include: - Strategic vision and leadership: Develop and implement a long-term strategy for research systems biology and bioinformatic activities to support a growing pipeline of RAS(ON) and novel targeted inhibitors. Lead and supervise

Executive Director, Analytics & Insights (NSCLC) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting directly to the Vice President, US Analytics & Insights, this role will serve as the analytics and insights leader dedicated to the Lung franchise, supporting launch planning and commercialization readiness for lung cancer assets. This individual will play a critical role in shaping franchise strategy through data-driven insights, while closely collaborating with forecasting, commercial, medical, and market access partners. This leader will operate as a player/coach, balancing hands-on analytical leadership with team development, and will be expected to personally contribute to high-priority strategic analyses while building and scaling a high-performing team. Candidates should bring deep oncology expertise, strong leadership capabilities, and a track record of translating complex data into actionable business insights within a fast-growing organization. This position is based out of our headquarters in Redwood City, CA. Responsibilities include: - Serve as the franchise lead for Analytics & Insights

Regional Insights and Engagement Director, Lung, Central Rockies Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Regional Insights and Engagement Director, Central Rockies is a field-based position focused on working closely with Lung Cancer Key Opinion Leaders (KOLs) at select institutions and accounts within the defined geography. This person is a RevMed clinical and product expert for Key Opinion Leaders and ensures that cross-functional resources are made available as appropriate. In this role, you will be a member of the commercial development team, and you will work closely with marketing, medical affairs, field sales, insights and analytics and other cross functional colleagues. You will help inform brand strategy, develop and execute KOL tactics and you will be evaluated in conjunction with individual performance and brand KPIs. This role will cover major academic institutions, accounts, and the Lung Key Opinion Leaders located in the Central Rockies. Essential Duties: - Designs, executes, and implements significant national

Associate Director, Statistical Programming Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Position requires 14+ years of Statistical Programming experience with exploratory-stage oncology clinical trials, providing programming support and oversight of one or more clinical programs (early or late phase) within Statistical Programming function. In addition to hands-on Programming, this position requires providing oversight and programming support and guidance for internal deliverables and regulatory submissions while ensuring conformance to CDISC standards and submission guidelines. Based on company needs, this position will be required to lead one or more early Phase or late phase studies/programs. Specific responsibilities include: - Effective collaborating with cross functional teams to provide programming timelines for various deliverables. - Provide SAS Programming technical support and guidance to programming team. - Oversight/participation in any internal/mock or regulatory authority audits. - Timeline and vendor management for deliverables, including submission-related activities, complying with regulatory standards (e.g., FDA 21 CFR Part 11, GxP). - Oversee the

Senior Director, Global Medical Affairs - GI Oncology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the GI Tumors Medical Affairs Strategy Lead, the Senior Director, Global Medical Affairs, will be responsible for developing and executing the Global Medical Affairs (GMA) strategy and tactical plans with a focus on launch readiness, launch implementation and life cycle management for an individual asset. The successful candidate will have a proven track record of developing and driving medical strategies with a focus on effectively communicating key scientific data through publications, medical information, medical communications, and congress activities. The successful candidate will also have experience gathering and analyzing insights through Advisory Boards, Key Opinion Leader (KOL) engagements and interaction with local/regional medical teams and translating those insights into tactics that optimize asset utilization and impact the drug lifecycle. This role requires close collaboration with cross-functional counterparts across Development, Research and Commercial as well as other internal partners,

Senior Director, Regional Medical Science Liaison Team Lead - East Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Executive Director of Field Medical Affairs, the Sr. Director will manage and coach a lung regional field medical team, oversee the regional field implementation plan and develop, deploy, and monitor key performance indicators and encourage individual professional development goals across the team. You will drive regional thought leader engagement strategy, foster scientific exchange, and lead insight generation strategies. Importantly, you will foster and identify opportunities to collaborate across functions and be instrumental in launch planning and execution. We are seeking a highly motivated and experienced leader to join our team as a Lung Regional Manager of Medical Science Liaisons. Key aspects of this front-line manager role will include: developing, mentoring, and coaching a team of MSL direct reports across approximately one half of the country. Required Skills, Experience and Education: - Collaborates with Field Medical Executive

Senior Director, Global Commercial Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the VP, Global Commercial Development Disease Area Lead, this newly created role will serve as a leader for continuing to build our global oncology marketing capabilities driving global commercial strategy at product team. Candidates should be passionate about leading cross-functional collaboration and contributing as both a strategic leader and hands-on driver in a growing organization. This position is primarily remote with travel required for scientific and team meetings. Specifically, you will be responsible for: - Partner across the company including with clinical development, medical affairs, market access, to drive indication strategy, shape brand strategies across the product team. - Ensure global readiness to drive successful launch planning, commercialization, and performance tracking across the U.S. and key ex-U.S. markets. - Execute global disease area strategy, brand strategies, including branding, positioning, messaging, and value propositions that guide regional affiliates and align with

Director, Forecasting (Lung) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Senior Director, U.S. Forecasting, the Director, U.S. Forecasting will be responsible for developing and executing forecasting models and analyses that support product strategy, performance management, and operational planning. This role focuses on building and maintaining short-term demand forecasts and patient-based models across U.S. oncology assets, enabling manufacturing, supply chain, and commercial decision-making. The Director will partner closely with cross-functional stakeholders to align on forecast inputs, assumptions, and outputs, while ensuring high-quality, timely deliverables. As a key contributor within the U.S. Forecasting function, this individual will execute forecasting processes in alignment with the broader U.S. forecasting strategy and contribute to ongoing improvements in forecasting capabilities, tools, and data integration. This position is based at our Redwood City, CA headquarters, with flexibility for remote candidates willing to travel regularly to the office. Responsibilities include: - Develop, maintain, and refine short-term demand forecasts across

Executive Director, GCP QA (Good Clinical Practice, Quality Assurance) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Executive Director of GCP QA is a senior leadership role responsible for setting and executing the global GCP quality strategy across clinical development programs. This position ensures compliance with regulatory requirements, industry standards, and company policies governing clinical trials. The role provides strategic oversight of GCP QA activities, including leadership of a high-performing QA team, governance of contract research organizations, and advancement of continuous improvement initiatives to uphold the highest standards of quality and patient safety. Serving as the GCP QA lead for late-stage clinical programs, this individual is accountable for GCP, GLP, and Pharmacovigilance/Safety oversight across multiple RevMed studies and represents QA in cross-functional and executive forums. The Executive Director will serve as a key advisor to senior leadership on clinical quality risk and regulatory readiness, helping to shape development strategy and enable successful regulatory outcomes.

Scientist II, Structural Biology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are looking for motivated structural biologist to join tour team to support multiple oncology therapeutic programs. The ideal candidate will have previous, hands-on experience in sample preparation, data acquisition and data analysis from both X-ray crystallography and cryo-EM. They will apply their expertise to form compound driven complexes, identify, and optimize crystallization/CryoEM conditions with the aim of determining high resolution structural information to drive small molecule design and mechanistic understanding. We're seeking a team player with enthusiasm to work in an interdisciplinary setting to drive toward new, cutting edge oncology therapeutics. Responsibilities - Plan and execute experiments with the aim of determining small molecule driven multi-protein complex structures by CryoEM and X-ray crystallography. - Perform cryo-EM grid screening, optimization, data collection and refinement to enable high-quality structure determination. - Interact with interdisciplinary teams (including chemists, computational chemists, biologists, project teams, and management)

ERP Systems Senior Manager (NetSuite) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a ERP Systems Senior Manager to serve as the primary owner and hands-on lead for NetSuite OneWorld, supporting our growing global operations and commercialization readiness. This is an individual contributor role responsible for both day-to-day system execution and longer-term ERP design and scalability. You will partner closely with Finance, FP&A, Accounting, Tax, Procurement, and IT to ensure NetSuite is accurate, compliant, scalable, and tightly aligned with business processes. This role combines deep hands-on system configuration and support with the ability to design and continuously improve ERP capabilities as the organization grows. You will play a critical role in maintaining financial integrity, supporting global entity expansion, optimizing inventory and product costing, and ensuring seamless integration across enterprise systems including Workday, Coupa, Concur, ADP, and middleware platforms. This role is pivotal in building sustainable, audit-ready ERP operations to support scale and

Senior Clinical Program Manager, Clinical Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: - Adhere to Clinical Standard Operating Procedures (SOP), Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines. - Be a team leader, providing guidance and oversight for the successful management of all aspects of clinical trials within timelines and designated program budgets. - Partner with cross-functional teams to manage, adjust, and revise project timelines and budgets as needed - Analyze data health metrics to be shared with stakeholders. - Actively partner with cross-functional teams and vendors to drive the query resolution and data listings review process to meet objectives in a timely and efficient process. - Conduct risk management, contingency, and scenario planning. - Supervise, communicate project status/issues, and problem solve to ensure project team goals are met. - Participate in the development of all study-related documentation, including study protocols. - Actively contribute in the selection and management of

Senior Product Manager, Biology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Senior Product Manager, Biology to shape products and capabilities that help Biology and Discovery teams design, execute, analyze, and learn from experiments faster, with trusted data and AI-enabled support. This role will define and deliver product strategy for Biology workflows, data products, and AI-enabled decision support on RevCore, our enterprise Data, Digital, and AI platform. The mandate is to improve experiment traceability, reduce manual data preparation, accelerate cross-study analysis, and make Biology insights easier to generate and act on. You will partner with scientists across Protein Science, Structural Biology, Screening Sciences, Sample Management, In Vivo Research, Pathology, Translational Research, Computational Biology, Data Science, ML Engineering, Data Engineering, IT, and platform teams to turn complex research workflows into intuitive, scalable products. Product surfaces may include experiment planning workflows, assay and screening result review, sample and reagent lineage, cross-study analysis, and

Senior Accountant, General Ledger, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated individual with a background in the life sciences industry to play a critical role in the accounting team. Reporting directly to the Senior Director, Accounting Europe, this newly created role will support the daily accounting operations operations across multiple European entities. This role will be responsible for maintaining accurate financial records, supporting month-end and year-end US GAAP and local GAAP close activities, preparing journal entries and reconciliations, VAT reporting, and ensuring compliance with company policies, internal controls, and applicable accounting standards. The role is located in Basel, Switzerland. - Perform day-to-day general ledger accounting activities for European entities. - Prepare journal entries such as cash, prepayments, accruals, fixed assets, leases and other month-end close adjustments. - Support monthly, quarterly, and annual close processes in accordance with company timelines. - Prepare balance sheet reconciliations and investigate variances in a timely

Director, Human Resources Technology – Workday Architect Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a rapidly growing biotech company, we are scaling our enterprise systems to support a dynamic workforce, evolving regulatory requirements, and complex financial operations. We are seeking a Workday Architect person to lead the design, development, and optimization of our Workday platform. - Oversee the end-to-end architecture, governance, and optimization of the Workday ecosystem including HCM, Learning, Talent, Peakon, Sana, and Advanced Compensation etc. - Provide architectural oversight and governance for external implementation partners, AMS providers, and integration vendors to ensure alignment with enterprise standards and strategic objectives. - Drive enterprise architecture decisions across the HR technology ecosystem by partnering with IT Enterprise Architecture, IT Security, and Finance teams to ensure scalable, compliant, and business-aligned solutions across Workday and interconnected enterprise platforms. - Lead adoption and governance of AI-enabled HR technologies, intelligent automation, and digital workflow capabilities across the Workday

Senior Director, Global CMC Lead Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a strategic, collaborative, and execution-oriented leader for the role of Senior Director, Global CMC Lead. The Senior Director, Global CMC Lead will provide cross-functional leadership and accountability for defining and executing integrated CMC strategies across development-stage and late-stage small molecule programs. This individual will partner closely with CMC cross functional teams, Regulatory, Quality, Clinical Development, and external partners to advance programs efficiently from development through commercialization readiness. The ideal candidate will bring deep expertise in small molecule pharmaceutical development and manufacturing, a strong understanding of the oncology drug development lifecycle, and the ability to thrive in a dynamic, fast-paced, and highly collaborative environment. Responsibilities: - Lead and execute integrated global CMC strategies across assigned development programs from early development through commercialization readiness. - Serve as the primary CMC lead on cross-functional program teams, accountable for CMC timelines, deliverables, risks,

Senior Director, Head of Early Development Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Head of Early Development Regulatory Affairs will lead global regulatory strategy for early-stage programs (pre-IND through Phase 2) across the portfolio. This leader will shape innovative and efficient regulatory pathways that enable rapid, science-driven development while positioning assets for long-term success. In addition to strategic leadership, this role will build and scale fit-for-purpose regulatory processes, frameworks, and capabilities to support portfolio growth. The position reports to the Head of Regulatory Sciences and serves as a key member of the Regulatory leadership team. Primary Responsibilities: Early Development Strategy - Lead global regulatory strategy from candidate selection through end-of-Phase 2. - Shape early clinical development strategy by providing regulatory leadership on dose-finding approaches and indication selection that enable accelerated and differentiated development pathways and position asset for global registration and Health Authority Engagement. - Oversee strategy and cross

Senior Manager, Clinical Business Systems Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager, Clinical Systems is a hands-on technical leader responsible for the daily administration, support, and ongoing enhancement of core clinical systems, including eTMF and CTMS, as well as the implementation and optimization of future platforms that support clinical operations (e.g., RBQM, Study Start-Up, IRT/RTSM). This role will actively perform and oversee system configuration, user management, periodic reviews, and validation activities, ensuring systems remain compliant, reliable, and inspection ready. The individual will work closely with Clinical Operations, Data Management, Regulatory, CSV, Quality, and external vendors to support business needs while maintaining GxP compliance. Key responsibilities in this role include: - Act as the hands-on system owner/lead for assigned clinical systems, supporting daily operations and issue resolution. - Perform user lifecycle management activities including provisioning, modifications, deactivation, and role-based access control. - Execute and document periodic user access reviews and audit trail